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Three-Dimensional Blood-Brain 
Barrier Model for in vitro Studies of 
Neurovascular Pathology
Hansang Cho1,3, Ji Hae Seo2, Keith H. K. Wong1, Yasukazu Terasaki2, Joseph Park3, 
Kiwan Bong1, Ken Arai2, Eng H. Lo2 & Daniel Irimia1
Blood–brain barrier (BBB) pathology leads to neurovascular disorders and is an important target for 
therapies. However, the study of BBB pathology is difficult in the absence of models that are simple 
and relevant. In vivo animal models are highly relevant, however they are hampered by complex, 
multi-cellular interactions that are difficult to decouple. In vitro models of BBB are simpler, however 
they have limited functionality and relevance to disease processes. To address these limitations, we 
developed a 3-dimensional (3D) model of BBB on a microfluidic platform. We verified the tightness 
of the BBB by showing its ability to reduce the leakage of dyes and to block the transmigration of 
immune cells towards chemoattractants. Moreover, we verified the localization at endothelial cell 
boundaries of ZO-1 and VE-Cadherin, two components of tight and adherens junctions. To validate 
the functionality of the BBB model, we probed its disruption by neuro-inflammation mediators 
and ischemic conditions and measured the protective function of antioxidant and ROCK-inhibitor 
treatments. Overall, our 3D BBB model provides a robust platform, adequate for detailed functional 
studies of BBB and for the screening of BBB-targeting drugs in neurological diseases.
Endothelial cells in the brain form an impermeable barrier, which delineates a unique chemical, func-
tional, and immunologic environment in a central nervous system (CNS)1,2. The tight junctions between 
endothelial cells in the blood-brain barrier (BBB) allow only small nutrient molecules and gases to diffuse 
across the BBB and limit the entrance of larger, potentially neurotoxic macromolecules, bacteria, and leu-
kocytes from the blood3,4. Recent studies reported that various neuropathology including neuroinflam-
mation5 and cerebral ischemia6–8 can induce the loss of the tightness or the destruction of BBB, allowing 
the leakage of serum proteins and the entrance of blood cells into the brain tissue. These processes could 
have relevance to various neurological diseases including Alzheimer’s disease (AD)9,10, Parkinson’s disease 
(PD)11–13, amyotrophic lateral sclerosis (ALS), brain edema, dementia, and multiple sclerosis14–16. Despite 
their importance for health and disease, studies that disrupt BBB in animal models pose significant chal-
lenges. The complexity of brain microenvironment reduces the ability to isolate the specific roles of the 
endothelial cells modulating the BBB tightness during neurovascular disorders from various factors in the 
blood stream or CNS. In vitro BBB models provide microenvironment conditions that are usually easier 
to control and quantify. However, their relevance is often limited due to over-simplification. They rely 
on 2 dimensional cellular contructs and are valuable only for end-point assays and the study of simple 
stimuli17,18. Recent models, relying on microscale technologies, could manipulate vertically stacked and 
planar BBB models, with limited capability for visualizing cellular interaction across the BBB5,19,20.
Here, we construct an in vitro BBB model by arranging endothelial monolayers in tube-like structures on 
a single-layered microfluidic platform21. We validate the tightness of the constructed model by visualizing 
the delayed dye leakage across our BBB, the expression of endothelial junction proteins, Zonula Occluden-1 
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(ZO-1) and VE-Cadherin along the cellular boundaries on top/bottom membranes, and by observing the 
blockage of neutrophil migration across the side membrane in the presence of standard chemoattract-
ant. We demonstrate the potential relevance of this model in studying neuroinflammation and cerebral 
ischemia, by measuring the effect of antioxidant scavenger, edaravone22–24, and Rho Kinase (ROCK) inhib-
itor, Y-2763225,26, on BBB permeability and protection against hypoxia-inducing oxidative damage.
Results and Discussion
We constructed our 3D BBB model in the form of a tube inside a single layered microfluidic platform. 
The tube of endothelial cells inside the platform is geometrically similar to small brain blood vessels. The 
single-layered platform is convenient for integrating with other functional components and assays, i.e. 
Figure 1. Schematic representation of a 3D in vitro BBB model and structural details. (a) A 3D 
BBB model consists of endothelial cells (EC) arranged in a cylindrical monolayer, forming a tight seal, 
and separating a “blood” compartment from an array of capillaries presenting chemotactic gradients, 
which simulate white blood-cell transmigration across the BBB. (b) The 3D BBB model is constructed 
by (1) coating an adhesive molecules, Poly-D-lysine (PDL), and a gel on polydimethyl-siloxane (PDMS) 
microstructures and a glass substrate, (2) plating brain endothelial cells (EC) first on the top and (3) later on 
the bottom surfaces, and (4) culturing to form tight monolayers. (c) The constructed BBB model has a lumen 
lined by confluent monolayers of endothelial cells on all surfaces, which resembles in vivo BBB. Prospective 
(1) and cross-sectional (2) views are presented. (d) The formation of a tight BBB is confirmed by the imaging 
of localized tight junction-involving proteins along cellular boundaries. Fluorescent Zonula Occluden-1  
(ZO-1) and Ve-Cadherin proteins are shown in left and right panels, respectively. Scale bars, 50 μm.
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chemotactic transmigration (Fig. 1). Our current model is static, with no fluid flow and no shear stress 
on the constructed model during culturing. To achieve faster maturation of barrier function, cells were 
seeded at high density on both the top and bottom surfaces and were confined along the compartments 
through the use of surface tension at the ends (Figs  1b, 2–3, Supplementary Fig. S1). The seeded cells 
formed strong attachment to the thin gel layer on microstructured PDMS substrate (Supplementary Fig. 
S2) and formed tight monolayers two or three days after plating. We validated the formation of endothe-
lial monolayers on 3D surfaces and the tightness of the junctions between adjacent cells by imaging each 
surface (Figs 1b, 4, supplementary Fig. S3). The confocal images showed a 3D membrane (Fig. 1c, 1) and 
monolayers of endothelial cells on all surfaces (Figs 1c, 2). The tightness of the BBB was confirmed by 
immunostaining of proteins: ZO-1 and VE-Cadherin, which are known to be responsible for the integrity 
of the BBB27,28. The tightness of the BBB was confirmed by immunostaining of proteins representative 
for the BBB tightness: ZO-1 and VE-Cadherin. We found ZO-1 and VE-cadherin expressed selectively 
along the cellular boundaries, in representative patterns (Fig.  1d). The localization of expressed ZO-1 
and VE-Cadherin on our model was not as clear as other endothelial monolayers on thin gel-coated or 
flat substrates, probably due to relatively thicker and softer gel compared to that reported in other litera-
ture29. Despite this limitation, our 3D BBB model could still be a convenient platform for various assays 
utilizing various surfaces: top and bottom surfaces for evaluating pathology-related assays destructing 
the BBB tightness, side surfaces for monitoring real-time penetration across the BBB upon the tightness 
destruction, and a single-layered platform for providing simple integration with other components.
The constructed BBB model could separate an outer (neural) environment from an inner (blood) 
environment. To demonstrate the separation, we first probed the transport of a dye across the endothelial 
layer through the side surfaces (Fig. 2). FITC-conjugated dextran at 40 KDa (D1844, Molecular Probes, 
Inc., Eugene, OR) was introduced into the lumen of the BBB model (Fig. 2a). While the dye penetrated 
across the endothelial layer, we evaluated the gradient of the dye priming into gel-filled channels out-
side. The outward flux of the dye was slower in the presence of the endothelium. The gradient peaked 
at about 7 minutes in the presence of the BBB, compared to less than 4 minutes when no barrier was 
present (Fig. 2b).
We also probed the transmigration of neutrophils across the endothelial layer, through the side sur-
faces, in response to a typical chemoattractant, IL8. Neutrophils plated inside the “blood” compart-
ment, become activated, rapidly changed their shape, and were observed moving under the effect of the 
chemoattractant. However, after two hours, we observed no neutrophils passing through the BBB and 
reaching the “neural” compartment and the migration channels (Fig. 2c and Supplementary information 
Movie M1, M3). In the absence of endothelial layers, neutrophils showed massive migration response, 
along the gradients of IL-8. In control experiments, few neutrophils could cross the layer of HUVEC. 
(Supplementary information Movie M2, M4, Fig. S4).
The inhibition of neutrophil transmigration by the BBB was also confirmed by confocal microscope 
imaging (Fig. 2d). In the absence of an endothelial cell layer, the migration speed of fluorescently tagged 
neutrophils along the gradient of IL-8 of 100 nM reached 25.3 ± 0.6 μm.min−1 from the observation for 
20 minutes. In the presence of endothelial layer, only one out of 300 neutrophils entered the “neural” 
compartment after 90 minutes and average speed was significantly lower, at 1.4 ± 1.4 μm.min−1. In neg-
ative control experiments, in the absence of IL-8, one neutrophil entered the “neural” compartment, 
migrated spontaneously into one channel (0.3 ± 0.3 μm.min−1), and returned back to the “blood” com-
partment (Fig. 2e).
To demonstrate the utility of the in vitro BBB model for probing the effect of neuroinflammation, we 
treated the constructed BBB with TNF-α (Fig.  3a), which has been previously reported to mediate of 
neuroinflammation and was detected in patients with neurological disorder at ~1 ng/mL30–32. In order 
to confirm the induction of neuroinflammation by TNF-α treatment in the BBB model, we treated the 
BBB model with TNF-α at 100 ng.mL−1 for 24 hours, extracted conditioned media from the “blood” 
compartment, and measured the changes in cytokine levels in the media in the “blood” compartment by 
using a 29-cytokine kit (ARY008, The Proteome Profiler Rat Cytokine Array Panel A Kit, R&D Systems, 
Inc.). We observed that TNF-α treatment elevated the release of several cytokines, including VEGF33, 
TIMP134, CINC135, CINC2–a/b36, CX3CL137, CXCL-1038, CCL2039, which are known to mediate a neu-
roinflammatory response compared to control group (no treatment) and confirmed that TNF-α treat-
ment effectively triggered inflammatory effect on our constructed BBB model (Fig.  3a,b). We further 
incubated the constructed BBB with TNF-α of 0/1/10/100 ng.mL−1 for various periods to evaluate its 
utility as neuro-inflammation model. We observed that ZO-1 proteins, which were highly expressed par-
ticularly along the cellular boundary before the TNF treatment, were reduced or even depleted in many 
regions after the treatment. TNF-α not only reduced the protein levels on the entire regions but also 
delocalized ZO-1 on the cellular boundary (supplementary Fig. S5). A box plot of averaged peak intensity 
indicated that BBB destruction was proportional to both of treatment time and the TNF-α concentra-
tion (i.e. TNF-α at 1 ng.mL−1 for 6 hours or TNF-α at 100 ng.mL−1 for 3 hours degraded ZO-1 by about 
20%) and TNF-α at 100 ng.mL−1 for 6 hours could reduce the level of ZO-1 by about 40% (Fig. 3c). To 
confirm that the disruption of the BBB post TNF-α treatment was not due to cell death, we verified the 
viability of the endothelial cells by standard assays (supplementary Fig. S6)40,41. These results imply that 
neuroinflammation could increase the BBB permeability, favoring the leakage of inflammatory cytokines 
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from/to the brain tissue. Our BBB model could be a convenient platform to systematically evaluate the 
destructive effects of various neuroinflammatory mediators on the integrity of the BBB model.
To demonstrate that the platform could be used as an ischemia model, we treated the constructed BBB 
with the OGD procedure (known for the ability to deplete oxygen and glucose) followed by reoxygena-
tion, which induced oxidative stresses and destructed the integrity of the BBB42. In order to confirm that 
the activation of ROS and ROCK by the oxidative stress, we subjected the constructed model to the OGD 
procedure for one hour, followed by reoxygenation for three hours, and then immunostained the cells for 
Figure 2. Constructed 3D BBB model shows reduced dye leakage and inhibited penetration of white blood 
cells. (a) The diffusion of FITC-dextran (M.W. 40 kDa) is significantly prevented for the first several minutes 
through the rat brain endothelial cells (EC) that form the BBB model (top). In the absence of the EC barrier, 
the fluorescent dextran diffuses into the side channels (bottom). (b) The EC layers significantly reduce the dye 
leakage and slow the formation of a gradient along channels next to the EC-loaded, left compartment. (c) The 
BBB model was evaluated for its ability to block the penetration of human neutrophils in the presence of BBB-
permeable chemoattractant Interleukin 8 (IL-8) in the right compartment. Neutrophils (NFs) were stained in 
green and loaded inside the left compartment. No neutrophils were observed to cross the BBB model. (d) The 
neutrophils enclosed with the EC layers are imaged in a confocal microscope. (e) Neutrophil migration along 
the IL-8 gradient is significantly inhibited and consequently averaged migration speed becomes nearly zero in 
the presence of the EC layers. (one-way ANOVA. *P < 1 × 10−7 by Tukey’s post-hoc test in comparison with 
other conditions). ncell = 18 for each condition. Data represent mean ± s.e.m. Scale bars, 50 μm.
www.nature.com/scientificreports/
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measuring ROS (Fig. 4a, supplementary Fig. S7). We also measured ROCK activity by phosphorylation 
of myosin light chain (p-MLC), which is upregulated by activated ROCK, within the endothelial cells 
(Fig.  4b, supplementary Fig. S8). We observed elevated level of ROS and p-MLC, by 2.8 and 3.0 fold, 
respectively, confirming the effect of oxidative stress on ROS production and ROCK activation in our 
BBB model (Fig. 4c). After an exposure to OGD procedure for up to an hour and following reoxygene-
tion for up to 3 hours, the viability decreased by less than 1%, as measured by propidium iodide-staining 
(supplementary Fig. S9). However, the levels of ZO-1 expression were significantly reduced by more than 
the half (Fig. 4d,e, supplementary Fig. S10). To restore BBB integrity, a clinically used antioxidant, edar-
avone and a ROCK inhibitor, Y-27632, which are known to protect BBB against oxidative stresses, were 
tested on the platform. The addition of edaravone and Y-27632 elevated the level of ZO-1 by 7 to 10% at 
three-hour after reoxygenation. At 6 hours after reoxygenation, cellular death increased by an additional 
1% and ZO-1 markers further reduced by 5%. These effects occurred after the addition of the protective 
compounds, suggesting limited protective effects of these compounds. The reason for the relatively low 
protection may be due to the fact that ischemic stress occurs not only due to oxidative stress but also 
due to hypoxia and other inflammatory effects. We envision that our platform could be employed for 
screening new compounds, which remove or counteract neurotoxic agents, including reactive oxygen 
species produced after ischemia or stroke. Our platform may also be useful for studying the contribution 
of various transporters43 and the emerging role of transcytosis systems44 to the functionality of BBB in 
health and disease. The platform may be further improved by the co-culture of astrocytes and pericytes 
with the BBB45 and by exploring the role of flow in the maintenance of BBB tightness over time46.
Conclusions
We designed a microfluidic platform that replicates several mechanical and functional features of the 
BBB in 3D. We validated the tightness of the BBB model by the presence of membrane proteins local-
ized along cellular boundary, by measurements of dye transport, and by the blocking of neutrophil 
Figure 3. BBB model response to neuroinflammation stimulus. (a) The changes in the levels of twenty-
nine cytokines were measured after stimulations of the BBB model with tumor necrosis factor alpha 
(TNF-α , upper row) compared to unstimulated baseline (second row). (b) Seven inflammation involving 
cytokines were noticeably further secreted by the BBB model with TNF-α treatment [100 ng.mL−1] for 
24 hours. (c) The levels of ZO-1 decreased with increasing treatment duration and concentration of TNF-α . 
The levels of ZO-1 decrease to 60% of control after 6 hours of exposure to TNF-α [100 ng.mL−1]. The dotted 
line represents the value of ‘Control’ group (no treatment). ncytokine = 4, ncell = 20 for each condition. Data 
represented as mean ± s.e.m.
www.nature.com/scientificreports/
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transmigration across the BBB in the presence of chemoattractants. The tight BBB in our model could 
be disrupted by exposure to TNF-α and in conditions of ischemia. Overall, this platform could be useful 
to study the roles of BBB in various diseases and for screening drugs candidates to modulate neuroin-
flammation and its consequences on BBB47.
Methods
Fabrication of microstructure and customized wells. Negative photoresists, SU-8 5 and SU-8 50 
(MicroChem, Newton, MA), were sequentially patterned using standard lithography on a 4 silicon wafer 
to create reversed features for cell migration channels and endothelial compartments. The height of these 
structures is 5 μm and 50 μm in height, respectively. A mixture of a base and a curing agent with a 10:1 
weight ratio (SYLGARD 184 A/B, Dowcorning, Midland, MI) was poured onto the SU-8 mold and cured 
at room temperature under vacuum for one hour and, subsequently, in an oven at 80 °C for more than 
3 hours. The cured PDMS was punched for fluid reservoirs and glued by uncured PDMS to a customized 
acrylic well plate of 6 mm in thickness for the extension of the medium reservoirs, which was machined 
by a laser-cut (Zing 24, Epilog Laser, Golden, CO) and then incubated at 80 °C overnight for bonding. 
The composite assembly was bonded to a glass-bottomed multiwell (P06-1.5-20-F, MatTek Corporation, 
Ashland, MA) or a glass-bottomed UniWell plate (MGB001-1-2-LG, Matrical Bioscience, Spokane, WA) 
using oxygen plasma at 50 mW, 5 ccm, for 30 seconds (PX-250, March Plasma Systems, Petersburg, FL)21.
Surface treatment of PDL and gel. Immediately after bonding, 10 μL of poly (D-lysine) solution 
(PDL, M.W. 70,000–150,000, 1.0 mg.mL−1, Sigma-Aldrich, St. Louis, MO) was injected into the each 
Figure 4. BBB model recovery after ischemia and the effect of protecting drugs. Ischemia is simulated 
by a two-step procedure of oxidative stress: oxygen-glucose deprivation (OGD) followed by reoxygenation 
(ReOx, abrupt supply of oxygen causing oxidative stress). The oxidative damage to the BBB model is 
confirmed by changes in the levels of (a) Reactive Oxygen Species (ROS) and (b) Rho Kinase (ROCK) 
activities. ROCK activity is evaluated from the change in phosphorylation of myosin light chain (p-MLC), 
which is upregulated by activated ROCK. (c) The expression of ROS and p-MLC increases three fold after 
oxidative stress compared to the absence of the stress. (d) The reduction of ZO-1 was partially prevented 
with the treatment of an antioxidant, edaravone [10 μM], from 46% to 53%. (e) The ROCK inhibitor 
protects ZO1 by 10 % with the treatment of Y27632 [100 μM] at 3 hours of reoxygenation. Student T-Test, 
two-tailed hypothesis, *P < 0.05 with no ischemia treatment, **P < 0.05 with no drug treatment, ncell = 64 for 
each condition. Data represent mean ± s.e.m. Scale bars, 50 μm.
www.nature.com/scientificreports/
7Scientific RepoRts | 5:15222 | DOi: 10.1038/srep15222
compartment and incubated at room temperature to promote cell adhesion. After 2 hours, we rinsed with 
autoclaved and 0.2 μm filtered water (AM9920, Life Technologies, Grand Island, NY). The PDL-coated 
platforms were filled with pH 7.4 collagen Type 1 (354249, Becton Dickinson, Franklin Lakes, NJ) at 2 mg. 
mL−1 and incubated at 37 °C for 30 minutes. The cured collagen in the endothelia compartments was 
replaced by a cell culturing medium (EGM-2 MV BulletKit: CC-3156 & CC-4147, Lonza Walkersville) 
supplemented with 1% P/S for overnight to promote the cellular growth. The flow of media was such 
that the gel in smaller migration channels remains inside the channels, to prevent spontaneous entrance 
of endothelial cells during plating.
Endothelial cell preparation and experiment. Medium including rat brain endothelial cells (RBE4, 
a cell line developed by INSERM1) at 60 million cells.mL−1 was loaded only in the compartments by 
removing an extra from both reservoirs and confining them within the compartments with a surface 
tension. The loaded cells adhered to the upper surface of the compartments when the platforms were 
placed in an inverted position for two hours in a culturing incubator at 37 °C supplied with 5% CO2. 
After the initial attachment to the upper surface, freshly isolated cells were gently reloaded and then 
attached to the lower surface at a normal position for two hours. After the attachment to both surfaces, 
an extra fresh medium of 100 μL was supplied to one of reservoirs and the customized wells and incu-
bated for overnight. The supply of fresh medium was maintained by adding new medium of 100 μL from 
one side and removing old one from the other side every day. For a neutrophil transmigration study, 
before experiments, cell membrane was labeled with a red fluorescent dye (PKH26PCL, Sigma-Aldrich) 
and nucleus with Hoechst 33342 (R37605, Life Technologies) following the manufacturer’s protocol and 
plated on only one compartment. The constructed 3D BBB was visualized with a confocal microscopy 
(LSM 710, Carl Zeiss, Thornwood, NY).
Neutrophil preparation and experiment. Human neutrophils were isolated from whole blood 
using EasySep Human Neutrophil Enrichment Kits (19257, STEMCELL Technologies, Vancouver, 
Canada) following the manufacturer’s protocol. After isolation, the cell membrane was stained with green 
fluorescent dye (PKH2 PCL, Sigma-Aldrich) following the manufacturer’s protocol. The stained neu-
trophils were re-suspended at a concentration of 10 million cells.mL−1 in a culturing medium, Iscove’s 
Modified Dulbecco’s Media (30-2005, American Type Culture Collection, Manassas, VA) supplemented 
with 20% FBS and 1% P/S. Chemokine for neutrophils, interleukin 8 (IL-8, 208-IL, R&D Systems, Inc., 
Minneapolis, MN) of 100 nM was added to the other compartment than an endothelial compartment 
and incubated for 2 hours to prime IL-8 along the gel-filled migration channels and the endothelial com-
partment. Stained neutrophils (NFs) at 10 million cells.mL−1 were injected into the endothelial compart-
ment and incubated at 37 °C supplied with 5% CO2 for 10 minutes before imaging. The neutrophils were 
cultured in a fully automated microscope (Eclipse Ti, Nikon Inc., Melville, NY) integrated with a heated 
incubating stage (LiveCell 05-11-0032 Rev B, Pathology Devices Inc., Westminster, MD), which was set at 
37.7 °C, 5% CO2, and 85% humidity, digitized in a real time (NIS Elements, Nikon Inc.), and the migra-
tion speed was calculated by counting the first neutrophil entering each migration channel using Image J.
TNF-α treatment. To mimic a neuroinflammatory condition, TNF-α (tumor necrosis factor-α , 
210-TA, R&D Systems, Inc.) was treated on a constructed BBB model. Brain endothelial cells were plated 
on a gel-coated microstructure and cultured for two or three days to fully develop monolayers in a normal 
culturing medium. Cells were further incubated in a culturing medium including TNF-α at various con-
centrations up to 6 hours for disrupting ZO-1 expression and 24 hours for measuring induced cytokines.
Oxygen-glucose deprivation procedure. To mimic an ischemic condition, oxygen-glucose depri-
vation (OGD) and reoxygenation were conducted. Briefly, a culturing medium was washed and replaced 
by no glucose Dulbecco’s Modified Eagle Medium (11966-025, Life Technologies). Cells were incubated 
at 37 °C in a humid chamber (Heidolph, incubator 1,000, Brinkmann Instruments,Westbury, NY) filled 
with an anaerobic gas (90% N2, 5% H2, and 5% CO2). OGD condition was aborted by changing an OGD 
medium to a culturing medium and further culturing cells in a normal incubator for reoxygenation.
Cell viability assay. To measure the fraction of dead endothelial cells, cells were incubated in a cul-
turing medium containing propidium iodide (PI) solution (P4864-10 ML, Sigma-Aldrich) at 1 mg.mL−1 
(1:200) for 15 min at 37 °C. Then, cells were washed twice by PBS, fixed by 4% PFA for 15 min, and 
imaged in a mounting oil including a DAPI. To quantify the number of dead endothelial cells, we took 
fluorescent images, automatically counted the number of nucleus by using CellProfiler (Broad Institute, 
Boston, MA), and manually counted red-stained spots, which co-localizes with blue-stained nucleus.
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